Daiichi-Sankyo is offering refunds for 340B overcharges on its breast cancer drug Enhertu and cholesterol drug Welchol for Oral Suspension.
Drug manufacturer Daiichi-Sankyo is offering 340B covered entities refunds for overcharges on metastatic breast cancer treatment Enhertu during Q1 2020 and on cholesterol medication Welchol for Oral Suspension during Q1 2022 and Q4 2022.
Lilly has asked a 340B covered entity to promptly repay it for “duplicate 340B/Medicaid discounts."
Drug manufacturer Eli Lilly asked a 340B covered entity last week to promptly repay it for “duplicate 340B/Medicaid discounts” and evaluate all Lilly prescriptions that it or its contract pharmacies dispensed for the last three years.
HRSA and OIG have no comment on the status of drug manufacturer civil monetary penalties and violation letters stemming from denials of 340B pricing to covered entities that use contract pharmacies.
The U.S. Department of Health and Human Services Office of Inspector General said yesterday it has no comment on the status of referrals from the U.S. Health Resources and Services Administration to fine eight drug manufacturers for failing
The AHA slammed PhRMA and NACHC's 340B reform alliance again, this time in its blog and related talking points.
The American Hospital Association has again blasted the drug industry’s alliance with community health centers for 340B reform, calling it “another misguided attempt by drug companies to dismantle [340B] so that they can continue to pad their billion-dollar
Novartis told a federal appeals court its revised 340B contract pharmacy policy doesn't affect its 340B contract pharmacy case awaiting the court’s decision.
Drug maker Novartis told a federal appeals court in Washington, D.C. Tuesday its revised 340B contract pharmacy policy “does not impact the legal arguments at issue” in its 340B contract pharmacy case awaiting the court’s decision.
Novartis announced today that it will let hospitals without an in-house pharmacy pick just one contract pharmacy location where Novartis will ship 340B discounted drugs.
Drug manufacturer Novartis this afternoon significantly beefed up its conditions on 340B pricing for hospitals.
Two others—GlaxoSmithKline and Pfizer—made similar moves on Friday. Novartis is the sixth to stiffen its 340B pricing policy since a federal appeals
ASAP 340B this week announced it hired an executive director and published an FAQ that responds to questions and criticism.
ASAP 340B, the nonprofit group that the drug industry and health centers formed to help advance their joint plan to remake the 340B program, has hired an executive director and published an FAQ that responds to questions and
AIDS Healthcare Foundation held a protest march Tuesday at the 340B Coalition winter conference in California against the PhRMA/NACHC alliance to change the 340B program.
AIDS Healthcare Foundation held two demonstrations Tuesday—one outdoors and loud, the other indoors and silent—at the 340B Coalition winter conference in California to protest against the new drug industry/community health center alliance to change the 340B program.